Terms: = Breast cancer AND KCNJ5, ENSG00000120457, 3762, P48544, KIR3_4, KATP1, GIRK4 AND Treatment
4 results:
1. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Montagna E; Pagan E; Cancello G; Sangalli C; Bagnardi V; Munzone E; Salè EO; Malengo D; Cazzaniga ME; Negri M; Peruzzotti G; Veronesi P; Viale G; Colleoni M
Anticancer Drugs; 2022 Jan; 33(1):e628-e634. PubMed ID: 34407044
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Metzger-Filho O; de Azambuja E; Bradbury I; Saini KS; Bines J; Simon SD; Dooren VV; Aktan G; Pritchard KI; Wolff AC; Smith I; Jackisch C; Lang I; Untch M; Boyle F; Xu B; Baselga J; Perez EA; Piccart-Gebhart M
Oncologist; 2013; 18(2):134-40. PubMed ID: 23359433
[TBL] [Abstract] [Full Text] [Related]
3. Protein expression of G-protein inwardly rectifying potassium channels (GIRK) in breast cancer cells.
Dhar MS; Plummer HK
BMC Physiol; 2006 Aug; 6():8. PubMed ID: 16945134
[TBL] [Abstract] [Full Text] [Related]
4. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines.
Plummer HK; Yu Q; Cakir Y; Schuller HM
BMC Cancer; 2004 Dec; 4():93. PubMed ID: 15603589
[TBL] [Abstract] [Full Text] [Related]
